Genes/SNPs associated with cHL prognosis, treatment-related secondary malignancies and toxicities
| Genes | SNP | Allele comparison | Treatment | Associations | Reference |
|---|---|---|---|---|---|
| UGT1A1 | TA repeat | TA6/6 vs. TA6/7/TA7/7 | ABVD/ChIVPP (70%), BEACOPP (11%), CHOP/COP/CHOEP (19%) + RT | Adverse OS | (69) |
| TA repeat | TA6/6 vs. TA6/7/TA7/7 | ABVD (66%), EBVP (22%), BEACOPP (12%) | Adverse FFP/OS/FFTF | (68) | |
| TRBP | rs784567 | TT/TC vs. CC | ABVD (52%), MOPPABVD (38%) | Adverse DFS | (71) |
| XPO5 | rs11077 | AA/CC vs. AC | ABVD (52%), MOPPABVD (38%) | Adverse DFS | (71) |
| PRDM1 | rs4946728 | A vs. C | RT/CHT (55%), RT only (41%), NA (4%) | Risk of any malignancy | (48) |
| rs1040411 | G vs. A | RT/CHT (55%), RT only (41%), NA (4%) | Risk of any malignancy | (48) | |
| GSTM1 | Deletion | Deletion vs. present | RT/CHT (63%), RT only (37%) | Risk of any malignancy/cancer within radiation field | (72) |
| KRT81 | rs3660 | CC vs. GG | ABVD (52%), MOPPABVD (38%) | Risk of neurologic toxicity | (71) |
| XPO5 | rs11077 | AC vs. AA/CC | ABVD (52%), MOPPABVD (38%) | Risk of pulmonary toxicity | (71) |
Abbreviations: BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, procarbazine; C(H)O(E)P: cyclophosphamide, (doxorubicin), vincristine, (etoposide), prednisolone; ChIVPP: chlorambucil, vinblastine, prednisolone, procarbazine; CHT, chemotherapy; DFS, disease-free survival; FFP, free from progression; FFS, failure-free survival; FFTF, freedom from treatment failure; MOPP, mustargen, oncovin, procarbazine, prednisone; NA, not available; OS, overall survival; RT, radiotherapy.